Spectrum Pharmaceuticals (Nasdaq: SPPI) announced results of a clinical study of the stability of Captisol-enabled Melphalan versus the currently marketed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE